Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 5/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | DNM1L | O00429 | 2/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435738 | 0.86 | HRH3 (0.41) | HRH3PIN1 | |
| SCHEMBL3435733 | 0.81 | DNM1L (0.38) | HRH3ACACBDNM1L | |
| SCHEMBL3435414 | 0.78 | SMN1; SMN2 (0.34) | HRH3 | |
| SCHEMBL3554282 | 0.78 | HRH3 (0.44) | HRH3PIN1MAP4K4ACACB | |
| SCHEMBL13999803 | 0.78 | ALDH1A1 (0.47) | HRH3 | |
| SCHEMBL13634268 | 0.77 | HRH3 (0.45) | HRH3PIN1DGAT2MAP4K4DNM1L | |
| SCHEMBL3435409 | 0.77 | DNM1L (0.39) | DNM1L | |
| SCHEMBL10278217 | 0.76 | HRH3 (0.48) | HRH3PIN1DGAT2MAP4K4ACACB | |
| SCHEMBL3435448 | 0.75 | ALDH1A1 (0.38) | — | |
| SCHEMBL3436228 | 0.73 | LMNA (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HRH3 338/4885PIN1 411/4885DGAT2 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.